We can’t show the full text here under this license. Use the link below to read it at the source.
GLP-1 and the Neurobiology of Eating Control: Recent Advances
GLP-1 and How the Brain Controls Eating: Recent Discoveries
AI simplified
Abstract
More than 1 billion people worldwide are affected by obesity, a chronic disease linked to increased mortality.
- Excess body fat is closely tied to higher energy intake.
- Most effective anti-obesity medications work by reducing appetite to facilitate weight loss.
- New glucagon-like peptide-1 () analogs show significant weight loss in clinical trials and initial real-world applications.
- These medications primarily lower food intake by activating GLP-1 receptors in the brain.
- The specific brain areas and neural pathways involved in GLP-1's effects on eating behavior are still under investigation.
AI simplified
Key numbers
15%
Weight Loss with Semaglutide
Percentage of body weight loss in clinical trials with semaglutide.
50% to 65%
Weight Regain After Cessation
Proportion of weight regained within a year after stopping treatment.
32%
Nonresponders to Treatment
Percentage of patients in the SELECT trial who did not achieve clinically meaningful weight loss.